Navigation Links
Newly Published Data from Large Study Support Cardiovascular Safety,of Avandia (Rosiglitazone Maleate)

Results show risk of heart attack comparable to two widely used diabetes medicines

LONDON, June 6, 2007- A study of more than 33,000 type 2 diabetes patients in a real-world setting was published today. This study shows that the incidence of hospitaliations for heart attack, and/or for a surgery known as coronary revascularization for patients on Avandia is the same as for other diabetes treatments. The study results were released in a paper titled “Coronary Heart Disease Outcomes in Patients Receiving Antidiabetic Agents” in Pharmacoepidemiology and Drug Safety.

These data, also described in a letter published online last week (May 30, 2007) in the medical journal The Lancet, are further evidence that the ischemic cardiovascular safety of Avandia is comparable to the most commonly used type 2 diabetes treatments – as evidenced in long-term prospective trials, such as ADOPT and DREAM. The findings conflict with a hypothesis generated by the recently published meta-analysis in the New England Journal of Medicine that raised concerns regarding ischemic risks with Avandia.

Based on an observational cohort study from a large U.S.managed-care database, this research was commissioned by GlaxoSmithKline as part of its commitment to the ongoing monitoring and assessment of the safety of Avandia. The study was designed to compare the risk of heart attack and coronary revascularization in type 2 diabetes patients taking Avandia, metformin or sulfonylurea – either alone, as two medicines combined and in combination with insulin. The study populations were matched to ensure that the cohort groups were similar in terms of their baseline risk factors for cardiovascular disease. Patients were followed for an avera
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Velcade (bortezomib) for Injection Based Therapies Achieved Survival Rates as High as 100 Percent in Newly Diagnosed Multiple Myeloma Patients
2. Newly Published Data Demonstrates Superiority of Cipralex Over Duloxetine for Acute Treatment of Depression
3. Adding Thalidomide to Standard Therapy Improves Survival in Newly Diagnosed Multiple Myeloma Patients Over Age 75
4. Newly Published Study Reveals Femara Improves Chances for Harder to Treat Early Breast Cancer Relapse in Postmenopausal Women
5. New Analysis of Data from WHI Provides Reassurance With Respect to Coronary Heart Disease For Newly Menopausal Women Considering Hormone Therapy
6. ECOG Phase III Newly Diagnosed Multiple Myeloma Trial (E4A03) Reports Lenalidomide Plus Low-Dose Dexamethasone Suggests Survival Advantage for Patients with Multiple Myeloma
7. MRI Detects Cancers in the Opposite Breast of Women Newly Diagnosed with Breast Cancer
8. Nymox Announces Positive Results from Newly Completed Long-term Study of NX-1207 for Benign Prostatic Hyperplasia
9. Newly Released Canadian Data Links Vaccines with Pervasive Developmental Disorder
10. New Phase 3 Study Published in The Lancet Evaluates Efficacy and Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination Therapy in Treatment-Experienced Adults With HIV
11. New Proof of Genisteins Efficacy and Safety for Osteopenia and Osteoporosis Published in Annals of Internal Medicine

Post Your Comments:
(Date:11/23/2009)...NEWYORK,Nov.23/PRNewswire/--Reportlinker.comannoun...alogue. ,, TheFutureoftheDiagnosticImagingMark...4603/The-Future-of-the-Diagnostic-Imaging-Market-t...r&utm_campaign=prnewswire ,, Descripti...015 ,, Summary ,, GlobalMarketsDirect,s"Th...
(Date:11/23/2009)...FollowingtheFDAapprovalsoftwonewtherapiesforNon-Ho...eenupdatedtoincludeofatumumab(Azerra(TM),GlaxoSmit...ocyticleukemia(CLL)andromidepsin(Istodax(R),Glouce...tswithcutaneousT-celllymphoma(CTCL). ,, FORTWAS...ntFDAapprovalshavepromptedtheNationalComprehensive...
(Date:11/23/2009)...NEWYORK,Nov.23/PRNewswire/--Reportlinker.comannoun...alogue. ,, HolterMonitoringSystems-AGlobalMark...4324/Holter-Monitoring-Systems---A-Global-Market-R...&utm_campaign=prnewswire ,, Cardiovascu...ts.High-riskpatientsneedtobecontinuouslymonitoredd...
Breaking Medicine Technology:Reportlinker Adds The Future of the Diagnostic Imaging Market to 2015 2Reportlinker Adds The Future of the Diagnostic Imaging Market to 2015 3Reportlinker Adds The Future of the Diagnostic Imaging Market to 2015 4Reportlinker Adds The Future of the Diagnostic Imaging Market to 2015 5Reportlinker Adds The Future of the Diagnostic Imaging Market to 2015 6Reportlinker Adds The Future of the Diagnostic Imaging Market to 2015 7Reportlinker Adds The Future of the Diagnostic Imaging Market to 2015 8Reportlinker Adds The Future of the Diagnostic Imaging Market to 2015 9Reportlinker Adds The Future of the Diagnostic Imaging Market to 2015 10Reportlinker Adds The Future of the Diagnostic Imaging Market to 2015 11NCCN Updates NHL Guidelines to Incorporate FDA Approvals of New Treatment Options 2NCCN Updates NHL Guidelines to Incorporate FDA Approvals of New Treatment Options 3Reportlinker Adds Holter Monitoring Systems - A Global Market Review 2Reportlinker Adds Holter Monitoring Systems - A Global Market Review 3Reportlinker Adds Holter Monitoring Systems - A Global Market Review 4Reportlinker Adds Holter Monitoring Systems - A Global Market Review 5China Biologic Named to Forbes Magazines Fifth Annual List of Asias 200 Best Under a Billion 14562 1China Biologic Named to Forbes Magazines Fifth Annual List of Asias 200 Best Under a Billion 14562 2China Biologic Named to Forbes Magazines Fifth Annual List of Asias 200 Best Under a Billion 14562 3Flextronics Announces Expansion of Medical Disposables Offering 5645 1Flextronics Announces Expansion of Medical Disposables Offering 5645 2NGM Biopharmaceuticals Appoints Dr Arthur D Levinson Former Genentech CEO to its Board of Directors 5640 1NGM Biopharmaceuticals Appoints Dr Arthur D Levinson Former Genentech CEO to its Board of Directors 5640 2NGM Biopharmaceuticals Appoints Dr Arthur D Levinson Former Genentech CEO to its Board of Directors 5640 3
(Date:11/23/2009)..., NEWYORK,Nov.23/PRNewswire/--Reportlinker.coman...scatalogue. ,, HandSanitizers-USMarketTrends ...Sanitizers---US-Market-Trends.html#utm_source=prne...re ,, Globalthreatsinthepast,suchasSARS,out...need,andimportanceofhandhygieneinpreventingthespre...
(Date:11/23/2009)...men who store fat on their waist in middle age are...n they get older, reveals a new study from the Sah...ished in the scientific journal Neurology . , "...at greater risk of dying prematurely due to a hear...r lecturer at the Sahlgrenska Academy. "If they ne...
(Date:11/23/2009)...acksburg, Va. The United States Department of Agr...rant to Virginia Tech and the University of Minnes...ticated turkey, Meleagris gallopavo. The funding w...tium to complete the genome sequencing using next-...me sequence, and identify genes and functions in t...
(Date:11/23/2009)..., NurturReceivesAccreditationforFivePopulationH...re-USNewswire/--ThePopulationHealthImpactInstitute...oannouncedthatPHII,sBoardofDirectorshasapprovedthe...TAP(TM))aftertwoyearsofdevelopment.Nurtur(TM),alif...hefirstorganizationtoreceivetheH-TAPaccreditations...
(Date:11/23/2009)...imal studies suggest that adding flaxseed oil to t...ost-menopausal women and women with diabetes, acco...ional Journal of Food Safety, Nutrition and Public...onal Research Center, in Cairo, Egypt, have studie...ted how flaxseed oil in the diet might delay the o...
Breaking Medicine News(10 mins):Health News:Reportlinker Adds Hand Sanitizers - US Market Trends 2Health News:Reportlinker Adds Hand Sanitizers - US Market Trends 3Health News:Reportlinker Adds Hand Sanitizers - US Market Trends 4Health News:Turkey Genome Sequencing Consortium awarded $0.9 million from USDA 2Health News:Population Health Impact Institute Launches Healthcare Transparency Accreditation Program(TM) 2Health News:Population Health Impact Institute Launches Healthcare Transparency Accreditation Program(TM) 3Health News:Flaxseed oil and osteoporosis 2
...tive Medicine (ACPM), a national medical specialty...th physicians who administer individual and commun...ncel or revise the medical content of its program,...reported in The New York Times, the show depicts a...
...mber of the,Sigma-Aldrich(TM) Group (Nasdaq: SIAL...xpansion of its solid-state services Pharmorphix(T...0 sq. ft. of laboratory capacity to,support this f...derstanding and,allows modification of the physica...
...ssisted Living Inspections, Rents Soar,and Problem..., DAVIS, Calif., Jan. 30 Elderly residents at,At...ued their protests over,exorbitant rent increases ...ervices at the facility., Atria Senior Living is ...
...r Corporation,(NYSE: SYK ) announced today that i...rence:, February 6, 2008 - 2:20 p.m. Eastern...l, Biotechnology and Medical Device Conferenc... the For Investors page. The,presentation for the ...
...rious, potentially life-threatening disease that a...a hemoglobin throughout the body. As part of the S...Institute on Aging (NIA), a component of the Natio... protected from most dangerous symptoms. The findi...
...8)Twenty-one boxes filled with 7,000 unique seed s...ped to the Svalbard Global Seed Vault, a facility ...e as a repository of last resort for humanitys agr...the Global Crop Diversity Trust, will fund its ope...
Other Medicine News:Health News:SAFC Pharma Expands Its Pharmorphix Solid State Chemistry Services 2Health News:SAFC Pharma Expands Its Pharmorphix Solid State Chemistry Services 3Health News:Left in the Dark and Facing Thousands in Rent Increases, Elderly Atria Senior Living Residents Protest; Call for Improvements 2Health News:Stryker to Present at Investor Conference 2Health News:Gene variant linked to moderated symptoms of beta-thalassemia 2Health News:African seed collection first to arrive in Norway on route to Arctic seed vault 2Health News:African seed collection first to arrive in Norway on route to Arctic seed vault 3
... ZOOM® Dual Power is a microprocessor-controll...th high voltage/low current and high current/low v.../low current section is ideal for sample fractiona...ions. The low voltage/high current section is for ...
GENIE POWER SUPPLIES (6, 12, and 24 volt, 10 amp output, without timer)
GENIE POWER SUPPLIES (6 and 12 volt, 1.5 amp output, without timer)
EPS 1001 Power Supply
Medicine Products: